Validation of phosphoprotein array assay for determination of human epidermal growth factor receptors downstream signalling phosphoproteins in breast carcinoma

Chrétien, Anne-Sophie; Chergui, Fadila; Bastogne, Thierry; Bouali, Sanae; Ramacci, Carole; Rouyer, Marie; Genin, Pascal; Leroux, Agnès; Merlin, Jean‐Louis

doi:10.1016/s1359-6349(08)71545-3

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Positive control consisting in standard protein extract from cell lines were added to each series. This technique was previously cross-validated with Western blot analysis (13).…”

Section: Western Blot Analysis Of Egfr and Pten Expressionmentioning

confidence: 99%

PTEN expression controls cellular response to cetuximab by mediating PI3K/AKT and RAS/RAF/MAPK downstream signaling in KRAS wild-type, hormone refractory prostate cancer cells

Merlin¹

2009

Oncol Rep

View full text Add to dashboard Cite

Abstract. Overexpression of epidermal growth factor receptor (EGFR) and mutation of pten tumor suppressor gene in human cancer cells leads to activated EGFR downstream signaling including PI3-kinase/AKT (PI3K/AKT) and/or mitogen-activated protein kinases (RAS/RAF/MAPK) and have been linked to resistance to anti-EGFR targeted therapies. Cetuximab is a chimeric IgG1 monoclonal antibody that binds the EGFR with high specificity and have been developed as promising therapeutic anticancer treatments in several solid tumors, including colorectal and head and neck squamous cell carcinomas. Cetuximab activity is related to PI3K/AKT and RAS/RAF/MAPK signaling pathways functionality and its activity has been shown to be higher in wild-type KRAS tumors. To study the influence of PTEN expression on cell response to cetuximab, we used wild-type KRAS, PTEN-null, EGFR overexpressing PC3 prostate cancer cells. Reintroduction of PTEN significantly reduced the constitutive overexpression of phosphorylated-AKT (p-AKT) and downstream kinases (p-GSK3ß and p-P70S6 kinase) as well as phosphorylated-ERK1/2 (p-ERK1/2) and consequently significantly restored cetuximab-induced cell growth inhibition and apoptosis induction. Taken together, the results achieved in the present study show that PTEN controls the cellular response to cetuximab in KRAS wild-type prostate carcinoma PC3 cells through the regulation of AKT phosphorylation and restoration of the functionality of EGFR downstream signaling. Extrapolation of these findings to clinical situation, suggests that the assessment of EGFR downstream signaling functionality could be proposed as a diagnostic response predictive marker for anti-EGFR targeted therapies.

show abstract

“…Positive control consisting in standard protein extract from cell lines were added to each series. This technique was previously cross-validated with Western blot analysis (13).…”

Section: Western Blot Analysis Of Egfr and Pten Expressionmentioning

confidence: 99%

PTEN expression controls cellular response to cetuximab by mediating PI3K/AKT and RAS/RAF/MAPK downstream signaling in KRAS wild-type, hormone refractory prostate cancer cells

Merlin¹

2009

Oncol Rep

View full text Add to dashboard Cite

show abstract

Validation of phosphoprotein array assay for determination of human epidermal growth factor receptors downstream signalling phosphoproteins in breast carcinoma

Cited by 1 publication

References 0 publications

PTEN expression controls cellular response to cetuximab by mediating PI3K/AKT and RAS/RAF/MAPK downstream signaling in KRAS wild-type, hormone refractory prostate cancer cells

PTEN expression controls cellular response to cetuximab by mediating PI3K/AKT and RAS/RAF/MAPK downstream signaling in KRAS wild-type, hormone refractory prostate cancer cells

Contact Info

Product

Resources

About